1. Home
  2. HBT vs CGEM Comparison

HBT vs CGEM Comparison

Compare HBT & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HBT

HBT Financial Inc.

HOLD

Current Price

$27.58

Market Cap

904.3M

Sector

Finance

ML Signal

HOLD

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$15.95

Market Cap

780.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HBT
CGEM
Founded
1920
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
904.3M
780.4M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
HBT
CGEM
Price
$27.58
$15.95
Analyst Decision
Buy
Strong Buy
Analyst Count
5
10
Target Price
$28.63
$28.80
AVG Volume (30 Days)
23.0K
770.4K
Earning Date
04-27-2026
03-30-2026
Dividend Yield
3.41%
N/A
EPS Growth
9.18
N/A
EPS
1.84
N/A
Revenue
N/A
N/A
Revenue This Year
$29.40
N/A
Revenue Next Year
$11.80
N/A
P/E Ratio
$14.69
N/A
Revenue Growth
N/A
N/A
52 Week Low
$19.46
$5.68
52 Week High
$29.88
$16.74

Technical Indicators

Market Signals
Indicator
HBT
CGEM
Relative Strength Index (RSI) 47.83 76.32
Support Level $24.39 $6.75
Resistance Level $27.85 N/A
Average True Range (ATR) 0.87 1.02
MACD -0.22 0.30
Stochastic Oscillator 29.16 85.22

Price Performance

Historical Comparison
HBT
CGEM

About HBT HBT Financial Inc.

HBT Financial Inc provides a comprehensive suite of business, commercial, wealth management, and retail banking products and services to individuals, businesses, and municipal entities throughout Central and Northeastern Illinois and Eastern Iowa. It operates through one reportable segment: community banking.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.

Share on Social Networks: